Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report

被引:1
|
作者
Chang, Haiyan [1 ]
Hu, Ting [1 ]
Hu, Jie [1 ]
Ding, Teng [2 ]
Wang, Qiong [1 ,3 ]
Cheng, Jing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zai Lab Shanghai Co Ltd, Med Affairs Dept, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp, Tongji Med Coll, 109 Machang Rd, Wuhan, Hubei, Peoples R China
关键词
breast cancer; human epidermal growth factor receptor 2; liver metastasis; margetuximab; TRASTUZUMAB; POLYMORPHISMS; BENEFIT;
D O I
10.1097/CAD.0000000000001466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [1] Margetuximab for HER2-Positive Breast Cancer
    Cuellar, Sandra
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 573 - 575
  • [2] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [3] Margetuximab for the treatment of HER2-positive metastatic breast cancer
    Tarantino, Paolo
    Morganti, Stefania
    Uliano, Jacopo
    Giugliano, Federica
    Crimini, Edoardo
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
  • [4] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Hans F Schoellhammer
    Felicia Hsu
    Courtney Vito
    Peiguo Chu
    Jinha Park
    James Waisman
    Joseph Kim
    BMC Cancer, 14
  • [5] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Schoellhammer, Hans F.
    Hsu, Felicia
    Vito, Courtney
    Chu, Peiguo
    Park, Jinha
    Waisman, James
    Kim, Joseph
    BMC CANCER, 2014, 14
  • [6] Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
    Gullo, G.
    Zuradelli, M.
    Sclafani, F.
    Santoro, A.
    Crown, J.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2204 - 2205
  • [7] Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy
    Li, Jiaping
    Lu, Qianyi
    Zhou, Hanxing
    Xu, Fei
    Huang, Jiajia
    Hong, Ruoxi
    Wang, Shusen
    ANTI-CANCER DRUGS, 2023, 34 (07) : 892 - 895
  • [8] A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
    Piras, Marta
    Panebianco, Martina
    Garibaldi, Matteo
    Roberto, Michela
    Merlonghi, Gioia
    Pellegrini, Patrizia
    Marchetti, Paolo
    CURRENT ONCOLOGY, 2021, 28 (03) : 1957 - 1961
  • [9] Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
    Isogai, Ayaka
    Kotani, Haruru
    Sawaki, Masataka
    Hattori, Masaya
    Yoshimura, Akiyo
    Kataoka, Ayumi
    Nozawa, Kazuki
    Ozaki, Yuri
    Endo, Yuka
    Nakakami, Akira
    Komaki, Rie
    Iwata, Hiroji
    SURGICAL CASE REPORTS, 2023, 9 (01)
  • [10] Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
    Ayaka Isogai
    Haruru Kotani
    Masataka Sawaki
    Masaya Hattori
    Akiyo Yoshimura
    Ayumi Kataoka
    Kazuki Nozawa
    Yuri Ozaki
    Yuka Endo
    Akira Nakakami
    Rie Komaki
    Hiroji Iwata
    Surgical Case Reports, 9